Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

Stock Information for Aytu BioPharma, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aytu BioPharma, Inc.

Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
Aytu BioPharma to Present at Upcoming October 2025 Conferences
11 Company Presentations Today at The MicroCap Rodeo Conference
Aytu BioPharma to Present at Upcoming September 2025 Conferences
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.